Radiopharmacies market seen reaching 8.2% CAGR by 2030

The radiopharmacies market is projected to grow from $11.12 billion in 2026 to $15.26 billion by 2030, driven by cancer rates, nuclear medicine demand and targeted radiopharmaceutical therapies. North America leads the market now, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Radiopharmacies sit at the center of diagnostic imaging and targeted therapy, so market growth tracks broader demand for cancer care and nuclear medicine. - The forecast points to rising demand for radiopharmaceutical production, logistics and cold-chain systems as healthcare systems expand access to these treatments.

What happened: - The Business Research Company published a radiopharmacies market report on July 7, 2026. - The report estimates the market will rise from $10.3 billion in 2025 to $11.12 billion in 2026. - The report forecasts the market will reach $15.26 billion by 2030, implying an 8.2% compound annual growth rate. - North America is the largest regional market in 2025. - Asia-Pacific is projected to be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa. - The company also offers a free sample of the report and the full report online: Download the free sample and View the full report.

The details: - The market’s recent expansion is tied to higher cancer and chronic disease prevalence, broader use of nuclear medicine imaging and stronger demand for precise diagnostic radiopharmaceuticals. - Hospital-based nuclear medicine departments have also expanded, adding to demand. - Regulatory scrutiny around the safe handling of radioactive materials has increased. - Future growth is expected to come from targeted radionuclide therapies, PET and SPECT imaging investment, personalized medicine, centralized radiopharmacy networks, and demand for specialized logistics. - The report highlights increased use of targeted radiopharmaceutical therapies in oncology, wider adoption of centralized radiopharmacy services, stronger radiation safety and compliance efforts, broader use in cardiology and neurology, and more spending on quality control systems. - Radiopharmacies are specialized facilities that prepare, compound and dispense radioactive materials for medical and research use. - These facilities support safe handling, accurate dosing and quality control for radiopharmaceuticals used in imaging and therapy.

Between the lines: - The market’s growth reflects a shift from one-off imaging support toward more integrated treatment platforms, especially as oncology adopts more targeted radioactive therapies. - The projected rise also suggests that operational infrastructure, not just drug development, is becoming a bigger business opportunity in nuclear medicine. - The World Health Organization said in February 2024 that more than 35 million new cancer cases are expected worldwide by 2050, up 77% from 20 million estimated in 2022. - That disease burden helps explain why radiopharmaceutical supply chains and radiopharmacy capacity are gaining importance.

What's next: - The market is expected to keep expanding through 2030 as healthcare systems invest in targeted therapies and advanced imaging. - Centralized radiopharmacy networks are likely to become more common as providers look for efficiency in dose preparation and distribution. - Companies and providers will likely face continued pressure to strengthen radiation safety, compliance and quality control.

The bottom line: - Radiopharmacies are moving from a niche support function to a growth market tied directly to cancer care, imaging innovation and the logistics of precision medicine.